June 2026 delivered a wave of new clinical data and regulatory updates that clarify the path forward for medical weight management. From the ACP’s new prescribing hierarchy to the launch of the Medicare GLP-1 Bridge and the rising potency of multi-agonists, the need for structured, physician-led care has never been more urgent.
Hair shedding is one of the most commonly reported but least-addressed sequelae of GLP-1-related weight loss, and it often overlaps with menopausal female pattern hair loss in the same patient. Aesthetic providers who can identify both presentations and offer structured interventions have a meaningful clinical and practice expansion opportunity.
BMI alone misses many high-risk patients. OBSCORE, a new Nature Medicine tool validated in approximately 200,000 participants, gives medical weight management providers a more precise framework for prioritizing interventions.
Botox® resistance has identifiable triggers and formulation-level solutions. Here’s what aesthetic providers need to know about immunogenicity and management.
Medical weight management providers have already figured out that the real revenue expansion in GLP-1 programs comes from the body contouring services layered on after significant weight loss. Aesthetic providers — already equipped with the skills and tools to serve these patients — are only starting to catch on.
Setting prices for aesthetic treatments is different from billing insurance. Here’s a practical framework for benchmarking your market and building a fee structure that’s profitable.
May 2026 brought a wave of new clinical data and market shifts that underscore a critical reality: prescribing a GLP-1 is only the beginning of obesity care. From managing the “off-ramp” of weight regain to addressing the complex reality of muscle mass changes, the need for structured, physician-led weight management programs has never been clearer.
A 2026 single-center observational study reports preliminary evidence that botulinum toxin may be deliverable transdermally for sebum reduction in oily and acne-prone skin. Here’s what the early data shows and what providers should watch for.
New randomized trial data confirms RF microneedling as a safe, effective standalone treatment for melasma in Fitzpatrick III-IV skin. Here’s what the evidence means for your protocols.
Physicians entering aesthetic medicine know how to diagnose. The consultation is different — it’s a goals-based conversation, not a problem-solving session. Here’s how to structure one that works.